---
title: "Celldex Therap | 8-K: FY2026 Q1 Revenue: USD 15 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285656957.md"
datetime: "2026-05-08T03:15:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285656957.md)
  - [en](https://longbridge.com/en/news/285656957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285656957.md)
---

# Celldex Therap | 8-K: FY2026 Q1 Revenue: USD 15 K

Revenue: As of FY2026 Q1, the actual value is USD 15 K.

EPS: As of FY2026 Q1, the actual value is USD -1.18, missing the estimate of USD -1.163.

EBIT: As of FY2026 Q1, the actual value is USD -90.19 M.

#### Cash Position

-   Cash, cash equivalents, and marketable securities were $451.5 million as of March 31, 2026, compared to $518.6 million as of December 31, 2025 .
-   Cash used in operating activities was $65.6 million for the first quarter of 2026 .
-   In April 2026, Celldex Therapeutics, Inc. raised $345.0 million in gross proceeds from a follow-on public offering, resulting in approximately $323.9 million in net proceeds .
-   As of March 31, 2026, Celldex Therapeutics, Inc. had 66.6 million shares outstanding .

#### Revenues

-   Total revenue for the first quarter of 2026 was $0.0 million ($15 thousand), a decrease from $0.7 million ($695 thousand) for the comparable period in 2025 .
-   Product development and licensing agreements generated $0.0 million in Q1 2026, down from $50 thousand in Q1 2025 .
-   Contracts and grants contributed $15 thousand in Q1 2026, compared to $645 thousand in Q1 2025 .

#### Operating Expenses

-   Research and development (R&D) expenses increased to $73.0 million in the first quarter of 2026 from $52.6 million in the comparable period of 2025, primarily due to increased barzolvolimab clinical trial and contract manufacturing expenses, and higher employee headcount .
-   General and administrative (G&A) expenses rose to $11.4 million in Q1 2026 from $10.8 million in Q1 2025, mainly due to increased barzolvolimab commercial planning expenses .

#### Operating Loss

-   The operating loss for the first quarter of 2026 was -$84.4 million, compared to -$62.7 million for the same period in 2025 .

#### Investment and Other Income, Net

-   Investment and other income, net, was $5.75 million for Q1 2026, down from $8.943 million for Q1 2025 .

#### Net Loss

-   The net loss for the first quarter of 2026 was -$78.7 million, or -$1.18 per share, compared to a net loss of -$53.8 million, or -$0.81 per share, for the comparable period in 2025 .

#### Operational Metrics

-   Enrollment was completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria (CSU) studies (EMBARQ-CSU 1 and 2), with 1,939 patients enrolled across 43 countries and over 500 sites .
-   The Phase 3 barzolvolimab cold urticaria (ColdU) and symptomatic dermographism (SD) study (EMBARQ-ColdU and -SD) is actively enrolling patients .
-   Enrollment has concluded in the Phase 2 study for prurigo nodularis (PN) and the Phase 2 study for atopic dermatitis (AD) .
-   Enrollment is complete in the multi-part Phase 1 study for CDX-622 in healthy volunteers, and a Phase 1 proof of mechanism (POM) study for CDX-622 in asthma patients was initiated in January 2026 .

#### Outlook / Guidance

-   Celldex Therapeutics, Inc. anticipates topline data from its Phase 3 barzolvolimab CSU studies in Q4 2026, with a BLA submission planned for 2027 . Topline data from the Phase 2 PN study are expected in summer 2026, and from the Phase 2 AD study in late 2026 . The company expects its current cash, cash equivalents, and marketable securities, combined with the net proceeds from the April 2026 public offering, to fund planned operations through 2028 .

### Related Stocks

- [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [INTOUCH INSIGHT ANNOUNCES Q1 2026 FINANCIAL RESULTS](https://longbridge.com/en/news/287124506.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)